Industry Focus
Healthcare: After Spinning Off Its Fastest-Growing Drugs, What's Next For Biogen?
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:22:14
- Mas informaciones
Informações:
Sinopsis
Competitors make headway against Teva Pharmaceutical's top-seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know.
